The estimated Net Worth of Larry Spitcaufsky is at least $87.2 Thousand dollars as of 21 November 2018. Larry Spitcaufsky owns over 1,280 units of Sonnet BioTherapeutics Inc stock worth over $33,819 and over the last 7 years Larry sold SONN stock worth over $53,380.
Larry has made over 2 trades of the Sonnet BioTherapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Larry bought 1,280 units of SONN stock worth $2,355 on 21 November 2018.
The largest trade Larry's ever made was selling 17,000 units of Sonnet BioTherapeutics Inc stock on 13 December 2017 worth over $53,380. On average, Larry trades about 3,656 units every 69 days since 2017. As of 21 November 2018 Larry still owns at least 41,480 units of Sonnet BioTherapeutics Inc stock.
You can see the complete history of Larry Spitcaufsky stock trades at the bottom of the page.
Larry's mailing address filed with the SEC is 16205 VIA DEL ALBA, PO BOX 891, , RANCHO SANTA FE, CA, 92067.
Over the last 8 years, insiders at Sonnet BioTherapeutics Inc have traded over $53,380 worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth $290,512 . The most active insiders traders include Pankaj Mohan, Donald J. Griffith, and Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of $21,474. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth $12,739.
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include: